How does Pien Tze Huang respond to market price speculation and high raw material costs?

Medical Network News on June 28.
A drug is hard to find, and the price is speculated.
.
.
Recently, the market price of Pien Tze Huang has encountered capital speculation, and the single tablet sales price of some online e-commerce platforms even exceeds 1,000 yuan
.
At the same time, in the capital market, Pien Tze Huang's stock price has also continued to rise, from 240 yuan per share to the closing price of 446.
90 yuan per share on June 25 within three months, and the company's total market value reached 269.
6 billion yuan
.
In response to the recent speculation of Pien Tze Huang tablets in the market, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
(referred to as "Pien Tze Huang Company") responded after learning of the market situation and reported to relevant departments to strengthen supervision and investigation, and adopt a series of measures to resolutely Maintain market order
.

Stable Supply and Standardized Terminal Sales
"Pharmaceutical Economic News" visited many chain pharmacies.
Some resident pharmacists and shop assistants stated that there are currently no Pien Tze Huang lozenges, but Pien Tze Huang lozenges are available in some stores
.
Some pharmacy staff said frankly that shortage of stock is also a special situation that happened recently.
Before the shortage of stock, the store had also done promotional activities.
The price was more than 600 yuan.
It can now be registered at the pharmacy and can be notified to purchase when the store is in stock
.
Regarding the current special market situation, the staff of the pharmacy told the "Pharmaceutical Economic News" that it may be related to the epidemic.
The Asian market, especially Southeast Asia, is very recognized for classic Chinese medicine products such as Pien Tze Huang.
With the continuous increase in export efforts, overseas The acceptance of traditional Chinese medicine products is also increasing
.
Earlier, Pien Tze Huang Company communicated with investors in its response to the interactive platform in May of this year.
Regarding consumer-related topics that "Pien Tze Huang can't buy", Pien Tze Huang said: "It will continue to pay close attention to the terminal market
.
" On the online platform, the current 590 yuan/tablet of Pien Tze Huang is indeed "hard to find.
" You can see on Tmall Pharmaceutical and JD Health that the price of Pien Tze Huang is more than 900 yuan/tablet.

.
The relevant person in charge of Pien Tze Huang Company pointed out that the company has always been adhering to the value concept of pharmacy with Germany and promoting virtue with medicine, actively fulfilling its social responsibilities, insisting on abiding by laws and regulations, and calling on consumers to purchase Pien Tze Huang products rationally and jointly care for national brands.
Business
.
In order to stabilize product supply, standardize terminal sales, and expand sales channels, Pien Tze Huang further stated that it will do a good job in product production and supply, increase the supply of self-operated channels and mainstream chain drugstore channels, and strive to alleviate the contradiction between market supply and demand; strengthen its own terminal stores Sales staff training, good consumption guidance, and irregular inspections to prevent high-priced sales; open the online sales of Tmall’s flagship pharmacy Pien Tze Huang to accelerate the layout of the JD flagship store; increase the supply of Pien Tze Huang capsules with the same quality and the same effect as Pien Tze Huang tablets To meet the diverse needs of consumers
.

Abnormal price supervision pays attention to speculation.

According to
data, in December 1999, Pien Tze Huang was restructured from the original Zhangzhou Pharmaceutical Factory established in 1956
.
In June 2003, it was listed and traded on the Shanghai Stock Exchange, and its business focused on the production and sales of proprietary Chinese medicines mainly in Pien Tze Huang
.
Similar to Yunnan Baiyao, the prescription and technology for producing Pien Tze Huang are listed as top secret by the State Administration of Traditional Chinese Medicine and the State Secrecy Bureau
.
Pien Tze Huang is also one of the first Chinese medicines to be protected by the state
.
Pien Tze Huang is mainly composed of bezoar, musk, panax notoginseng and snake gall.
The drug is used for clearing heat and detoxification, cooling blood to remove blood stasis, reducing swelling and pain, and is used for acute chronic viral hepatitis caused by febrile blood stasis, carbuncle furuncle, bruises and injuries.
And various inflammations
.
It is worth noting that since the bezoar and musk in Pien Tze Huang tablets are natural ingredients, the price increase of Pien Tze Huang for many years is related to the increase in the price and cost of raw medicinal materials
.
In 2005, 2007, 2012, and 2016, the market price of Pien Tze Huang increased due to the increase in the cost of the main raw materials and restricted use.

.
In January 2020, Pien Tze Huang announced that in view of the increase in the main raw materials and labor costs of Pien Tze Huang products, the company has decided to increase the domestic market retail price of Pien Tze Huang tablets from 530 yuan/tablet to 590 yuan/from the date of the announcement.
The supply price will be increased by about 40 yuan/tablet; the supply price in overseas markets will be increased by about US$5.
80/tablet
.
In addition, Pien Tze Huang's overseas reputation has also continued to magnify market demand
.
As early as 2003, Pien Tze Huang Company stated that Pien Tze Huang had formed a relatively high reputation and market share in domestic and overseas markets.
“Overseas sales to Hong Kong, Macao, Taiwan, Southeast Asia, North America and Australia accounted for about half of the company's total sales.

From 1988 to 2003, Pien Tze Huang The average annual foreign exchange earning from exports exceeds 10 million U.
S.
dollars, and it has been in the forefront of foreign exchange earning by individual products of Chinese patent medicines in the country for many consecutive years
.
” It is not difficult to see that although the market retail price of Pien Tze Huang has risen in the past years, the price is still relatively high in the face of domestic and overseas market consumer demand.
Within the range of normal market fluctuations
.
The short-term price "abnormal fluctuations" and possible hot money speculation and malicious price increases behind the figures have been highly valued by market regulatory authorities
.

High-value varieties in the capital market are well-received
.

Traditional Chinese medicine continues to receive favorable policies, which promotes the rapid development of the Chinese medicine industry in the direction of standardization, standardization, and internationalization
.
From March 25, 2013, the State Administration of Traditional Chinese Medicine issued the "Chinese Medicine Preventive and Health Care (Preventive Treatment) Service Technological Innovation Outline (2013-2020)" to the promulgation of the "People’s Republic of China Law on Traditional Chinese Medicine" at the end of 2016.
Support for the pharmaceutical industry has officially risen to legal heights
.
The "19th National Congress" report clearly put forward the call for "implementing a healthy China strategy", which brings huge opportunities for the development of Chinese medicine companies
.
A large number of traditional Chinese medicine companies, such as Yunnan Baiyao, Tongrentang, Pien Tze Huang, and Guang Yuyuan, have gradually gained recognition from the capital market in the process of continuing to focus on the development of the past.
In the past year, the share prices of many listed Chinese medicine companies have shown a clear upward trend.

.
With the aura of "national double top secret" (top secret formula and top secret craftsmanship) and national first-class Chinese medicine protected varieties, Pien Tze Huang has become a "business card" for the Chinese traditional Chinese medicine industry to inherit classics and expand overseas markets
.
In order to consolidate its position in the treatment of liver diseases, Pien Tze Huang has increased its investment in product development, and invests resources in research on liver diseases and liver cancer.
In terms of research and development costs, the total investment in research and development in 2020 will be 97.
55 million yuan
.
The industry generally believes that the traditional Chinese medicine industry is undoubtedly the most certain growth industry in the pharmaceutical segment.
Whether it is macro policy support or capital flow preference, it is conducive to long-term long-term Chinese medicine capital market, with outstanding industrial chain advantages and upstream medicinal resources Branded Chinese medicine companies with strong control capabilities, a solid brand position, and relatively good independent pricing capabilities are bound to have greater industrial value
.